(NASDAQ:NVAX) saw strong trading volume on Monday after an insider bought additional shares in the company. BlackRock Group LTD now owns 161,349 shares of the biopharmaceutical company's stock valued at $335,000 after buying an additional 1,043 shares during the last quarter.
In other Novavax news, Director James F. Young sold 175,000 shares of the company's stock in a transaction that occurred on Thursday, August 31st. In a transaction dated August 31, 2017, the shares were put up for sale at an average price of $1.06, raking in a sum of $185,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 7.87%, and has a solid year to date (YTD) performance of -3.17% which means that the stock is constantly adding to its value from the previous fiscal year end price. California State Teachers Retirement System now owns 454,699 shares with a value of $518,000. The disclosure for this purchase can be found here. Corporate insiders own 4.00% of the company's stock.
Moscow getting contradictory signals from U.S. on Putin-Trump meeting
The president has always denied Russian Federation influenced his win - as has Vladimir Putin . But I just asked him again, and he said he absolutely did not meddle in our election.
Several research analysts have recently commented on the stock.
On November 8 Cantor Fitzgerald kept the company rating at "Hold" targeting a price of $2.00. Zacks Investment Research downgraded Novavax from a "buy" rating to a "hold" rating in a report on Thursday, January 12th. Ladenburg Thalmann Financial Services upgraded shares of Novavax from a "neutral" rating to a "buy" rating and set a $1.60 price target on the stock in a research report on Wednesday, August 9th. Novavax presently has a consensus rating of "Hold" and a consensus price target of $3.12. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company's stock. Piper Jaffray Companies restated a "hold" rating and issued a $1.50 target price on shares of Novavax in a report on Wednesday, July 26th. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of -4.28.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Tuesday, November 7th. The company beat the analyst EPS Estimate with the difference of $0.02. The firm earned $3.20 million during the quarter, compared to the consensus estimate of $4.02 million. Novavax had a negative return on equity of 189.14% and a negative net margin of 1,908.41%. Novavax's quarterly revenue was up 158.5% compared to the same quarter last year. analysts expect that Novavax, Inc. will post -0.61 EPS for the current fiscal year.
Miami, Notre Dame Fans Have Slippery Brawl During College Football Game
One of the videos abruptly ends after 40 seconds, when a man wearing a Miami shirt tells one of the other fans in the fight to stop.
Novavax, Inc. (NASDAQ:NVAX)'s stock had its "outperform" rating reaffirmed by research analysts at FBR & Co in a report issued on Wednesday.
Hedge funds have recently modified their holdings of the company.
Alliancebernstein L.P. raised its holdings in shares of Novavax, Inc. During the same period a year ago, the company earned ($0.24) earnings per share. JPMorgan Chase & Co. increased its position in Novavax by 40.1% during the second quarter. Stifel Financial Corp now owns 21,990 shares of the biopharmaceutical company's stock valued at $160,000 after buying an additional 400 shares during the last quarter. Rhumbline Advisers now owns 346,968 shares of the biopharmaceutical company's stock valued at $399,000 after buying an additional 23,410 shares in the last quarter. Voya Investment Management LLC lifted its stake in Novavax by 18.6% in the second quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company's stock valued at $3,073,000 after buying an additional 371,295 shares during the period. Finally, GSA Capital Partners LLP increased its position in Novavax by 38.7% during the second quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company's stock worth $185,000 after acquiring an additional 69,600 shares during the period.
Nationwide Fund Advisors Buys New Holdings in Antares Pharma, Inc. (ATRS)
It fall, as 16 investors sold ATRS shares while 14 reduced holdings. 112 funds opened positions while 620 raised stakes. Atlantic Tru Limited Liability Co holds 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS) for 125,000 shares.
Institutional investors now hold around $141 million or 40.6% in NVAX stock.